A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 757
- Registration Number
- NCT04513912
- Locations
- ๐จ๐ฟ
A Shine S R O, Plzen, Czechia
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธSW Biomedical Research LLC, Tucson, Arizona, United States
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1284
- Registration Number
- NCT04508023
- Locations
- ๐บ๐ธ
Morehouse School of Medicine, Atlanta, Georgia, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธFranciscan Research Center, Tacoma, Washington, United States
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Conditions
- Metastatic Castration-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 696
- Registration Number
- NCT04497844
- Locations
- ๐บ๐ธ
Seattle Cancer Care Alliance, Seattle, Washington, United States
๐บ๐ธHouston Metro Urology, Houston, Texas, United States
๐ง๐ชJolimont, Haine-St-Paul, Belgium
Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD
- Conditions
- Healthy
- Interventions
- Other: No intervention
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 830
- Registration Number
- NCT04494360
- Locations
- ๐บ๐ธ
PRA Health Sciences, Lenexa, Kansas, United States
๐บ๐ธResearch Centers of America, LLC, Hollywood, Florida, United States
๐บ๐ธEndeavor Clinical Trials, LLC, San Antonio, Texas, United States
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1074
- Registration Number
- NCT04487080
- Locations
- ๐ฏ๐ต
National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-shi, Japan
๐ฏ๐ตNational Cancer Center Hospital, Chuo Ku, Japan
๐ฏ๐ตWakayama Medical University Hospital, Wakayama, Japan
A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: JNJ-64281802 High doseDrug: JNJ-64281802 Medium doseDrug: JNJ-64281802 Low doseDrug: JNJ-64281802 Dosing Regimen XDrug: JNJ-64281802 Dosing Regimen YDrug: JNJ-64281802 Dosing Regimen Z
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT04480736
- Locations
- ๐บ๐ธ
SUNY Upstate Medical University, Syracuse, New York, United States
A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants
- Conditions
- Renal Insufficiency
- Interventions
- Drug: JNJ-56136379
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04474210
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธThe Texas Liver Institute, San Antonio, Texas, United States
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
- Conditions
- Colitis, UlcerativeHealthy
- Interventions
- Drug: PlaceboDrug: JNJ-66525433
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT04457960
- Locations
- ๐ฉ๐ช
Charitรฉ Research Organisation GmbH, Berlin, Germany
A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04453189
- Locations
- ๐ณ๐ฑ
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04452994